Macrolide lactams
Medchemexpress LLC Tacrolimus (FK506) | 104987-11-3 | MFCD00869853 | 99.6% | 803.48 Da | C44H69NO12 | 5 MG
Tacrolimus (FK506) analytical standard intended for research and analytical applications. Tacrolimus is a macrolide immunosuppressant that binds FK506 binding protein and inhibits calcineurin, affecting T-lymphocyte signal transduction. This reference material is supplied for assay calibration, method development, and quality control in analytical workflows.
- High-purity reference material (99.6%).
- Intended for analytical and research use, including assay calibration and method development.
- Available in small mass quantities suitable for analytical workflows (e.g., 5 mg).
- Provides a stable, characterized standard for quality control.
- Supplied with documentation for purity and identity.
Selleck Chemical LLC Tacrolimus monohydrate
Tacrolimus monohydrate (Tacrolimus FK506) is a macrolide antibiotic that primarily acts as an inhibitor of calcineurin phosphatase by binding to FK506 binding protein (FKBP) This inhibition blocks calcium-dependent processes including interleukin-2 gene transcription nitric oxide synthase activation cell degranulation and apoptosis and also has immunosuppressive neuroregenerative and neuroprotective properties
AdipoGen Ascomycin high purity
Chemical. CAS 104987-12-4. Formula C43H69NO12. MW 792. Isolated from Streptomyces sp. Macrolide antibiotic. Ethyl analog of FK506. Strong immunosuppressant. Binds to the FK-506-binding protein FKBP12. This complex inhibits calcineurin protein phosphatase 2B PP2B. Suppresses the production of T helper type 1 Th1 interferon and IL-2 and Th2 IL-4 and IL-10 cytokines in T lymphocytes and preferentially inhibits the activation of mast cells. Anti-inflammatory. Used for topical treatment of inflammatory skin diseases. Potently inhibits anti-IgE-induced histamine and cytokine release and reduces IgE-dependent p38 MAPK activation in human basophils. Inhibits basophil degranulation at the initial phase of allergic skin reactions. Antifungal. Antimalaria compound. Anticonvulsant antiepileptic.
AdipoGen Ascomycin high purity
Chemical. CAS 104987-12-4. Formula C43H69NO12. MW 792. Isolated from Streptomyces sp. Macrolide antibiotic. Ethyl analog of FK506. Strong immunosuppressant. Binds to the FK-506-binding protein FKBP12. This complex inhibits calcineurin protein phosphatase 2B PP2B. Suppresses the production of T helper type 1 Th1 interferon and IL-2 and Th2 IL-4 and IL-10 cytokines in T lymphocytes and preferentially inhibits the activation of mast cells. Anti-inflammatory. Used for topical treatment of inflammatory skin diseases. Potently inhibits anti-IgE-induced histamine and cytokine release and reduces IgE-dependent p38 MAPK activation in human basophils. Inhibits basophil degranulation at the initial phase of allergic skin reactions. Antifungal. Antimalaria compound. Anticonvulsant antiepileptic.
Medchemexpress LLC N-(1-oxoheptyl)-D-gamma-glutamyl-(6R)-6-carboxy-L-lysyl-D-alanine | 79335-75-4 | 99.9% | 502.57 g/mol | C22H38N4O9 | 25mg
FK-565 is a nucleotide oligomerization domain-1 (NOD1) ligand FK-565 induces murine model with arteritis[1]
Apexbio Technology LLC FK 866 hydrochloride(Synonyms: FK866 hydrochloride, APO866 hydrochloride, Daporinad hydrochloride), 10mg, CAS: 658084-64-1 (free base).
FK 866 hydrochloride (CAS 658084-64-1 free base) is a potent inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase) an enzyme essential for NAD biosynthesis exhibiting activity with IC50 values ranging from 0 09 nM to 27 2 nM By blocking NAD synthesis FK 866 disrupts ATP production induces mitochondria membrane depolarization and triggers autophagy independent of caspase activation It selectively targets hematologic cancer cells such as AML lines sparing normal hematopoietic progenitor cells FK 866 demonstrates antitumor efficacy in vivo significantly suppressing growth in AML-M4 and Namalwa xenograft models
Sigma Aldrich Fine Chemicals Biosciences Tacrolimus for system suitability European Pharmacopoeia (EP) Reference Standard | 109581-93-3 | MFCD11045918 |
Tacrolimus for system suitability European Pharmacopoeia (EP) Reference Standard | Mol Wt: 822.03 | 109581-93-3 | MFCD11045918 |
Apexbio Technology LLC Tacrolimus monohydrate 109581-93-3 100mg
Tacrolimus monohydrate also identified as FK506 monohydrate is a macrolide immunosuppressive compound functioning via inhibition of calcineurin-mediated signaling pathways Specifically tacrolimus forms a complex with FK506-binding protein (FKBP12) subsequently blocking calcineurin phosphatase activity thus suppressing T-cell activation and diminishing interleukin-2 (IL-2) transcription levels In cellular assays tacrolimus demonstrates inhibition of calcineurin with IC50 values typically ranging between 0 1-1 0 nM Due to its targeted modulation of immune signaling this compound remains widely utilized in biomedical research particularly for investigations related to immune response mechanisms autoimmune disorder models transplantation biology and signal transduction pathways relevant to lymphocyte activation and cytokine expression
Apexbio Technology LLC Tacrolimus monohydrate 109581-93-3 1g
Tacrolimus monohydrate also identified as FK506 monohydrate is a macrolide immunosuppressive compound functioning via inhibition of calcineurin-mediated signaling pathways Specifically tacrolimus forms a complex with FK506-binding protein (FKBP12) subsequently blocking calcineurin phosphatase activity thus suppressing T-cell activation and diminishing interleukin-2 (IL-2) transcription levels In cellular assays tacrolimus demonstrates inhibition of calcineurin with IC50 values typically ranging between 0 1-1 0 nM Due to its targeted modulation of immune signaling this compound remains widely utilized in biomedical research particularly for investigations related to immune response mechanisms autoimmune disorder models transplantation biology and signal transduction pathways relevant to lymphocyte activation and cytokine expression
Medchemexpress LLC E/Z-FK-506 26,28-allylic ester rearrangement impurity | 131944-48-4 | >90.0% | 804.02 | C44H69NO12 | 10 MG
(E/Z)-FK-506 26,28-allylic ester rearrangement impurity (FK506-A) is an impurity of tacrolimus used as a reference standard for analytical and stability studies. It is intended for research and analytical applications to identify, quantify, and qualify impurity profiles; consult the certificate of analysis for storage and handling details.
- Reference impurity of tacrolimus for analytical method development.
- Suitable for impurity identification, reporting, and qualification studies.
- High-purity material for reliable chromatographic and mass spectrometric analysis (>90.0%).
- Supplied as a solid for laboratory use; consult the certificate of analysis for storage instructions.
- Molecular formula C44H69NO12 and molecular weight 804.02 for compound identification.
Sigma Aldrich Fine Chemicals Biosciences Tacrolimus monohydrate European Pharmacopoeia (EP) Reference Standard | 109581-93-3 | MFCD11045918 |
Tacrolimus monohydrate European Pharmacopoeia (EP) Reference Standard | Mol Wt: 822.03 | 109581-93-3 | MFCD11045918 |